Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 145 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Multiple Ascending Dose (MAD) Cohorts Clear all

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Safety
Interventions: MRX-8, Placebo; Drug
Lead sponsor: MicuRx; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obesity
Interventions: BMF-650; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: LY4005130, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Olmsted Syndrome
Interventions: KM-023, Placebo; Drug
Lead sponsor: Orvida Pharma (formerly Kamari Pharma); Network
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy Volunteers, Dyslipidaemia
Interventions: NNC0491-6075, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Cypress, California

Conditions: Major Depressive Disorder
Interventions: (2R,6R)-Hydroxynorketamine hydrochloride, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: AMG 127, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Lake Forest, California • Aventura, Florida

Conditions: Healthy Participants
Interventions: AZD4144 Part A, AZD4144 Part B, Placebo Part A, Placebo Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Healthy Volunteers
Interventions: SL-325, Placebo (Normal Saline); Biological · Other
Lead sponsor: Shattuck Labs, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Chemotherapy-induced Diarrhea
Interventions: SK10, Placebo; Drug
Lead sponsor: Guangzhou Zhiyi Biotechnology Co., Ltd.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Parkinson's Disease
Interventions: MT101-5; Drug
Lead sponsor: Mthera Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy
Interventions: TD-5202, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: HIV Infections
Interventions: VH4770359, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Malaria
Interventions: MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg; Biological · Other
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Weight Management
Interventions: ASC30 Injection, for subcutaneous use or placebo; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Graves Disease
Interventions: MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD; Biological
Lead sponsor: Merida Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Torrance, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Healthy
Interventions: KBP-7072, Placebo; Drug · Other
Lead sponsor: KBP Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Pain
Interventions: MEB-1170, Placebo; Drug
Lead sponsor: Mebias Discovery, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions: ABI-1968; Drug
Lead sponsor: Antiva Biosciences; Industry
Eligibility: 25 Years to 50 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 6
States / cities: Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more

Conditions: Healthy Volunteers
Interventions: (Part A) MKND-201, Placebo, (Part B) MKND-201; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 40 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Geographic Atrophy, Age-related Macular Degeneration
Interventions: RO7669330, Syfovre™, Izervay™; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more

Conditions: Healthy Adult Participants
Interventions: TBD11, Placebo; Drug
Lead sponsor: Gates Medical Research Institute; Other
Eligibility: 19 Years to 55 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Participants
Interventions: SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg, SAD IMG-004 400mg, SAD IMG-004 600mg, SAD Placebo 30mg, SAD Placebo 100mg, SAD Placebo 200mg, SAD Placebo 400mg, SAD Placebo 600mg, MAD IMG-004 50mg, MAD Placebo 50mg, MAD IMG-004 150mg, MAD Placebo 150mg, MAD IMG-004 300mg, MAD Placebo 300mg, FE IMG-004 150mg; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Daytona Beach, Florida

Search by objective public record fields.

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

A Study of LY4005130 in Healthy Participants

Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine

A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants

Phase 1 Study of SL-325 in Healthy Volunteers

A Sequential Single and Multiple Ascending Dose (SAD/MAD) Study of SK10 Powders in Healthy Adult Subjects

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity

NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

A Study to Assess the Safety of MEB-1170 in Healthy Subjects

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MKND-201 in Healthy Volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, and Behavior in the Body of TBD11

Study to Evaluate IMG-004 in Healthy Participants